AtriCure (ATRC) Competitors $35.03 -0.28 (-0.79%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATRC vs. NUVA, SILK, CSII, ATRI, LUNG, ITGR, IART, ATEC, OFIX, and SRDXShould you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include NuVasive (NUVA), Silk Road Medical (SILK), Cardiovascular Systems (CSII), Atrion (ATRI), Pulmonx (LUNG), Integer (ITGR), Integra LifeSciences (IART), Alphatec (ATEC), Orthofix Medical (OFIX), and Surmodics (SRDX). These companies are all part of the "medical" sector. AtriCure vs. NuVasive Silk Road Medical Cardiovascular Systems Atrion Pulmonx Integer Integra LifeSciences Alphatec Orthofix Medical Surmodics NuVasive (NASDAQ:NUVA) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking. Is NUVA or ATRC more profitable? NuVasive has a net margin of 2.32% compared to AtriCure's net margin of -8.70%. NuVasive's return on equity of 12.17% beat AtriCure's return on equity.Company Net Margins Return on Equity Return on Assets NuVasive2.32% 12.17% 4.88% AtriCure -8.70%-8.12%-6.21% Does the media refer more to NUVA or ATRC? In the previous week, AtriCure had 3 more articles in the media than NuVasive. MarketBeat recorded 3 mentions for AtriCure and 0 mentions for NuVasive. AtriCure's average media sentiment score of 1.59 beat NuVasive's score of 0.30 indicating that AtriCure is being referred to more favorably in the news media. Company Overall Sentiment NuVasive Neutral AtriCure Very Positive Which has stronger valuation & earnings, NUVA or ATRC? NuVasive has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than NuVasive, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuVasive$1.23B1.70$40.41M$0.5079.50AtriCure$447.57M3.82-$30.44M-$0.83-42.20 Do analysts recommend NUVA or ATRC? AtriCure has a consensus price target of $43.11, indicating a potential upside of 23.07%. Given AtriCure's stronger consensus rating and higher possible upside, analysts clearly believe AtriCure is more favorable than NuVasive.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuVasive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AtriCure 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in NUVA or ATRC? 99.1% of AtriCure shares are owned by institutional investors. 0.5% of NuVasive shares are owned by insiders. Comparatively, 3.2% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in NUVA or ATRC? NuVasive received 242 more outperform votes than AtriCure when rated by MarketBeat users. However, 69.06% of users gave AtriCure an outperform vote while only 63.75% of users gave NuVasive an outperform vote. CompanyUnderperformOutperformNuVasiveOutperform Votes80063.75% Underperform Votes45536.25% AtriCureOutperform Votes55869.06% Underperform Votes25030.94% Which has more volatility and risk, NUVA or ATRC? NuVasive has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. SummaryAtriCure beats NuVasive on 10 of the 18 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get AtriCure News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRC vs. The Competition Export to ExcelMetricAtriCureSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.71B$4.56B$5.07B$8.66BDividend YieldN/A39.56%5.10%4.06%P/E Ratio-42.2024.93100.6017.27Price / Sales3.8255.021,195.1369.06Price / CashN/A51.7641.0336.35Price / Book3.675.486.345.87Net Income-$30.44M$13.76M$119.64M$225.66M7 Day Performance-6.46%-6.52%-5.13%-1.34%1 Month Performance22.61%2.19%-2.72%1.15%1 Year Performance-15.59%50.62%31.10%24.02% AtriCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRCAtriCure3.5183 of 5 stars$35.03-0.8%$43.11+23.1%-16.5%$1.71B$447.57M-42.201,200Short Interest ↓Positive NewsNUVANuVasiveN/A$39.75flatN/AN/A$2.08B$1.23B79.503,000Analyst ForecastSILKSilk Road Medical0.4472 of 5 stars$27.49flatN/AN/A$1.12B$177.13M-20.07410CSIICardiovascular SystemsN/A$20.00flatN/A+0.0%$843.96M$239.84M-20.62780Analyst ForecastATRIAtrionN/A$459.92flatN/AN/A$809.46M$181.60M43.23720Analyst ForecastLUNGPulmonx3.4717 of 5 stars$6.45-4.0%N/A-41.5%$254.71M$68.68M-4.39250Short Interest ↓ITGRInteger3.3599 of 5 stars$134.91-1.9%N/A+49.6%$4.52B$1.60B41.6410,500Analyst RevisionNews CoveragePositive NewsIARTIntegra LifeSciences2.9858 of 5 stars$23.27-0.2%N/A-41.5%$1.80B$1.54B-258.533,946Positive NewsATECAlphatec4.3723 of 5 stars$8.73-4.4%N/A-27.7%$1.24B$482.26M-6.82700OFIXOrthofix Medical2.0849 of 5 stars$17.60-5.6%N/A+74.0%$671.79M$746.64M-5.621,634SRDXSurmodics4.3381 of 5 stars$38.09-0.2%N/A+13.8%$543.54M$126.08M-47.02376Analyst ForecastPositive News Related Companies and Tools Related Companies NUVA Competitors SILK Competitors CSII Competitors ATRI Competitors LUNG Competitors ITGR Competitors IART Competitors ATEC Competitors OFIX Competitors SRDX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATRC) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRC Stock Alerts